SYNG Pharmaceuticals Inc. (SYNG Pharma) is a pre-clinical stage biotechnology company dedicated to developing next generation diagnostic and therapeutic against endometriosis. The company is developing a novel peptide, SP011, to inhibit a target now known for its role in the proliferation of cells. SYNG Pharma has a potential to develop a treatment that would be a much needed alternative to currently available, partly ineffective, hormonal therapy. There are many other potential applications of SYNG Pharma technology including the treatment of fibroids and uterine sarcoma; breast and prostate cancer which may be further developed depending upon corporate interests and an opportunity for partnership.